Venom Peptides Targeting KV1.3 Channels: A Growing Toolkit for Autoimmune Disease Treatment
Venom-derived peptides that block the KV1.3 potassium channel show therapeutic potential in autoimmune diseases, with one analog already completing Phase 1 clinical trials.
Quick Facts
What This Study Found
Venom-derived KV1.3 inhibitors show efficacy in animal models of multiple autoimmune diseases, and the ShK analog dalazatide has completed Phase 1 trials for psoriasis.
Key Numbers
Dalazatide Phase 1 complete; efficacy in RA, psoriasis, MS models; KV1.3 target for IBD, AD, PD, fibrosis
How They Did This
Narrative review of venom peptide pharmacology, KV1.3 biology in autoimmune disease, and clinical development progress.
Why This Research Matters
KV1.3 is upregulated in the specific immune cells driving autoimmune diseases, making targeted peptide inhibitors a precision medicine approach with potentially fewer side effects than broad immunosuppression.
The Bigger Picture
The expanding list of conditions where KV1.3 is a target, combined with the growing library of venom-derived inhibitors, suggests this class of peptide therapeutics will continue to advance toward clinical use.
What This Study Doesn't Tell Us
Most efficacy data from animal models. Only dalazatide has reached clinical trials. Brain penetration remains a challenge for neuroinflammatory applications.
Questions This Raises
- ?Will dalazatide advance to Phase 2/3 trials?
- ?Can venom peptides be modified for brain penetration to treat neuroinflammatory diseases?
- ?Which autoimmune disease is the best initial clinical target for KV1.3 inhibitors?
Trust & Context
- Key Stat:
- Phase 1 complete Dalazatide, a sea anemone venom peptide analog, has completed Phase 1 clinical trials for psoriasis
- Evidence Grade:
- Review citing animal model efficacy data and one Phase 1 clinical trial. Promising but most applications are preclinical.
- Study Age:
- Published in 2020. KV1.3-targeted therapies continue to be developed.
- Original Title:
- The voltage-gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides.
- Published In:
- Biochemical pharmacology, 181, 114146 (2020)
- Authors:
- Tajti, Gabor, Wai, Dorothy C C, Panyi, Gyorgy, Norton, Raymond S
- Database ID:
- RPEP-05156
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How do venom peptides treat autoimmune diseases?
Certain venom peptides specifically block KV1.3 potassium channels that are highly expressed on the immune cells causing autoimmune diseases. By selectively suppressing these disease-driving cells without broadly suppressing the immune system, venom peptides could offer targeted treatment with fewer side effects.
What is dalazatide?
Dalazatide is a modified version of a sea anemone venom peptide (ShK) that blocks KV1.3 channels. It has completed Phase 1 clinical trials for mild-to-moderate psoriasis, making it the first venom-derived KV1.3 inhibitor tested in humans.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05156APA
Tajti, Gabor; Wai, Dorothy C C; Panyi, Gyorgy; Norton, Raymond S. (2020). The voltage-gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides.. Biochemical pharmacology, 181, 114146. https://doi.org/10.1016/j.bcp.2020.114146
MLA
Tajti, Gabor, et al. "The voltage-gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides.." Biochemical pharmacology, 2020. https://doi.org/10.1016/j.bcp.2020.114146
RethinkPeptides
RethinkPeptides Research Database. "The voltage-gated potassium channel KV1.3 as a therapeutic t..." RPEP-05156. Retrieved from https://rethinkpeptides.com/research/tajti-2020-the-voltagegated-potassium-channel
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.